Form 4 for WHWK Whitehawk Therapeutics, Inc.
Accepted 2026-05-18 16:02:43 ET · period of report 2026-05-14 · accession 0001355758-26-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-05-18 16:02 | 2026-05-14 | WHWK | Castelein Caley | Dir | A - Grant | $3.92 | +255.1K | 274.8K | +1,295% | +$1000.0K |
| DI | 2026-05-18 16:02 | 2026-05-14 | WHWK | Castelein Caley | Dir | A - Grant | $8,124,996.24 | +2.07M | 2.07M | New | +$16841.13B |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-14 | A | A | 255,102 | $3.92 | 274,796 | D | — | — | |
| 2 | Derivative | Pre-Funded Warrant (right to buy) | 2026-05-14 | A | A | 2,072,756 | $8,124,996.24 | 2,072,756 | I See footnote | $0.0001 · — to — | 2,072,756 Common Stock | (F2) Subject to the terms and conditions set forth in the Pre-Funded Warrant, the holder thereof may, at any time and from time to time on or after May 14, 2026, exercise the Pre-Funded Warrant until it has been exercised in full. Pursuant to the terms of the Pre-Funded Warrant, the holder cannot exercise any of the Pre-Funded Warrant to the extent the holder and its affiliates, including the Reporting Person, would beneficially own, after any such exercise, more than 4.99% of the outstanding Common Stock. (F2) Subject to the terms and conditions set forth in the Pre-Funded Warrant, the holder thereof may, at any time and from time to time on or after May 14, 2026, exercise the Pre-Funded Warrant until it has been exercised in full. Pursuant to the terms of the Pre-Funded Warrant, the holder cannot exercise any of the Pre-Funded Warrant to the extent the holder and its affiliates, including the Reporting Person, would beneficially own, after any such exercise, more than 4.99% of the outstanding Common Stock. (F3) Pre-Funded Warrant held by KVP Capital, LP. The Reporting Person is the Managing Director of KVP Capital. The Reporting Person disclaims beneficial ownership of the Pre-Funded Warrant held by KVP Capital, except to the extent of his pecuniary interest therein. |